AC
VNDA icon

AXQ Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

AXQ Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,557
Closed -$234K – 1278
2025
Q4 		$234K Buy
+26,557
New +$146K 0.05% 511
2025
Q2 		– Sell
-20,106
Closed -$92.3K – 794
2025
Q1 		$92.3K Buy
+20,106
New +$93.7K 0.04% 445
2023
Q3 		– Sell
-12,713
Closed -$83.8K – 604
2023
Q2 		$83.8K Buy
+12,713
New +$81.5K 0.1% 247

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AXQ Capital's VNDA Position: Q1 2026 in Review

AXQ Capital sold out of Vanda Pharmaceuticals (VNDA) in Q1 2026, closing a stake of 26,557 shares — an estimated $234K sold.

AXQ Capital first reported a position in VNDA in Q2 2023 and held it in 3 quarters. The position peaked at $234K in Q4 2025. 171 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • AXQ Capital reported no remaining Vanda Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • AXQ Capital sold 26,557 Vanda Pharmaceuticals shares in Q1 2026, an estimated $234K.
  • AXQ Capital first reported a position in Vanda Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • AXQ Capital's Vanda Pharmaceuticals position peaked at $234K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.